Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (12067)	1/13/2003 2:04:01 PM
From: Findit	Read Replies (1) \| Respond to of 13094

Sergio news on CLGY - SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY) announced today that Mr. Julian Baker and his brother Dr. Felix Baker have resigned from the Company's Board of Directors. The Bakers are managing partners of Baker Brothers Investments and Baker/Tisch Investments and advise members of the Tisch Family on their investments in Cellegy. K. Michael Forrest, Cellegy's Chairman, President and CEO said, "We would like to express our gratitude to Julian and Felix Baker for their many contributions as board members over the past two years. Their technical expertise, knowledge of the capital markets and general good business sense has been instrumental in helping us grow the company to its current level. We understand their desire to re-balance on their efforts over all of their portfolio companies and appreciate the significant amount of time and effort they devoted to Cellegy." "Cellegy has significantly strengthened its financial position and entered into a significant marketing partnership in the past quarter," said Julian Baker. "We are pleased with Cellegy's recent progress and look forward to the future." Cellegy Pharmaceuticals is a specialty pharmaceutical company focused in the areas of gastroenterology, the treatment of sexual dysfunction in males and females and the treatment of various women's health disorders. This press release contains forward-looking statements. Many factors could cause actual results to differ materially from the Company's expectations. Among, but not limited to, these are the outcomes of clinical trials, unexpected regulatory delays, or other difficulties in obtaining marketing approvals and commercializing its products. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2001. SOURCE Cellegy Pharmaceuticals, Inc. /CONTACT: Richard Juelis, Vice President, Finance & CFO, or K. Michael Forrest, Chairman, President & CEO, both of Cellegy Pharmaceuticals, Inc., +1-650-616-2200/ /Web site: cellegy.com / (CLGY) CO: Cellegy Pharmaceuticals, Inc. ST: California IN: HEA MTC SU: PER (END) Dow Jones Newswires 01-13-03 1332ET